Hyperfine, Inc. (HYPR)
| Market Cap | 92.39M +48.4% |
| Revenue (ttm) | 15.33M +30.7% |
| Net Income | -34.78M |
| EPS | -0.40 |
| Shares Out | 99.27M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,230,363 |
| Open | 0.9800 |
| Previous Close | 0.9821 |
| Day's Range | 0.9100 - 0.9800 |
| 52-Week Range | 0.8370 - 2.2200 |
| Beta | 1.40 |
| Analysts | Strong Buy |
| Price Target | 2.17 (+133.16%) |
| Earnings Date | Aug 12, 2026 |
About HYPR
Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners. The company also offers support and technical assistance services, as well as Hyperfine Image Viewer, a cloud picture archiving and communication system. It serves intensive care units, neurology offices, emergency departments, and comprehensive and primary stroke accredi... [Read more]
Financial Performance
In 2025, Hyperfine's revenue was $13.56 million, an increase of 5.22% compared to the previous year's $12.89 million. Losses were -$35.57 million, -12.64% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for HYPR stock is "Strong Buy." The 12-month stock price target is $2.17, which is an increase of 133.16% from the latest price.
News
Hyperfine announces European launch of next-generation Swoop system
Hyperfine (HYPR) announced the European launch of the next-generation Swoop system powered by the latest advancement in Optive AI software. This marks a significant milestone in the company’s global e...
Hyperfine Announces European Launch of Next-Generation Swoop® System
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine initiates the launch of the next-gen Swoop® system in Europe, beginning global expansion of its most advanced portable MRI technology. .
Hyperfine announces formation of Neurosurgery Advisory Council
Hyperfine (HYPR) announced the formation of its Neurosurgery Advisory Council, a multidisciplinary group of neurosurgeons who will provide expertise to help inform the potential role of portable ultra...
Hyperfine Forms Global Neurosurgery Advisory Council to Support Expansion of Portable MRI in Neurosurgical Care
GUILFORD, Conn.--(BUSINESS WIRE)--Leading neurosurgeons will help guide the role of the Swoop® system in neurosurgical care, including workflow, product capabilities, and evidence.
Hyperfine says Swoop system scan volume in the U.S. hits ‘record milestones’
Hyperfine (HYPR) announced the achievement of scan volume milestones in key hospitals and neurology clinics, demonstrating accelerating clinical utilization and adoption of the Swoop(R) system through...
Hyperfine Swoop® System Scan Volume in the United States Hits Record Milestones Across Multiple Sites of Care
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine announces Swoop® system scan volume milestones at key hospitals and neurology clinics, demonstrating accelerating adoption across the US.
Hyperfine Transcript: Jefferies Global Healthcare Conference 2026
Strong Q1 growth and robust financial outlook are driven by innovative portable MRI technology, regulatory clearances, and diversified revenue streams. Clinical data supports near-parity with conventional MRI, while future plans target expanded indications and broader market reach.
Hyperfine to join Russell 2000, Russell 3000 Indexes
Hyperfine (HYPR) announced that Hyperfine is expected to join the broad-market Russell 3000 Index and the small-cap Russell 2000 Index at the conclusion of the June 2026 Russell Reconstitution, accord...
Hyperfine to Join Russell 2000® and Russell 3000® Indexes
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine is expected to join broad-market Russell 3000® Index & small-cap Russell 2000® Index at the conclusion of June 2026 Russell Reconstitution.
Hyperfine presents PRIME study results on portable MRI at SAEM meeting
Hyperfine (HYPR) announced the presentation of results of the PRIME study at the Society for Academic Emergency Medicine 2026 Annual Meeting. PRIME is a single-center, prospective, randomized controll...
Hyperfine Announces Presentation of Results from the PRIME Study Showing Portable MRI Substantially Reduces Time to Imaging in Emergency Departments
GUILFORD, Conn.--(BUSINESS WIRE)--PRIME study results show bedside portable MRI cut order-to-scan time vs conventional MRI and identified critical ED findings.
Hyperfine Transcript: AGM 2026
The meeting confirmed a quorum, elected five directors, and ratified the auditor appointment. No shareholder questions were raised, and all proposals passed with requisite votes. Forward-looking statements were noted as subject to risks in SEC filings.
Hyperfine management to meet virtually with Lake Street
Virtual Meeting to be held on May 21 hosted by Lake Street.
Hyperfine management to meet virtually with Oppenheimer
Virtual Meeting to be held on May 21 hosted by Oppenheimer.
Hyperfine price target raised to $2 from $1.60 at B. Riley
B. Riley analyst Yuan Zhi raised the firm’s price target on Hyperfine (HYPR) to $2 from $1.60 and keeps a Buy rating on the shares.
Hyperfine reports Q1 EPS (9c), consensus (9c)
Reports Q1 revenue $3.9M, consensus $3.54M. “Our execution in Q1 was strong. We delivered our second-highest revenue quarter to date with over 80% year-over-year revenue growth, driven by our accelera...
Hyperfine still sees FY26 revenue $20M-$22M, consensus $20.04M
Management continues to expect cash burn for the full year 2026 to be approximately $26M-$28M, representing a 10% decline at the midpoint as compared to full year 2025. Published first…
Hyperfine files to sell 1.08M shares of Class A common stock for holders
16:42 EDT Hyperfine (HYPR) files to sell 1.08M shares of Class A common stock for holders
Hyperfine Earnings Call Transcript: Q1 2026
Q1 2026 revenue rose 83% year-over-year to $3.9 million, with gross margin exceeding 50% and strong adoption across hospitals, neurology offices, and international markets. Guidance for 2026 is reiterated, projecting $20–$22 million in revenue and continued margin expansion.
Hyperfine Earnings release: Q1 2026
Hyperfine released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Hyperfine Quarterly report: Q1 2026
Hyperfine has published its Q1 2026 quarterly earnings report on May 12, 2026.
Hyperfine Slides: Q1 2026
Hyperfine has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 12, 2026.
Hyperfine, Inc. Reports First Quarter 2026 Financial Results
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic ...
Hyperfine Registration statement: Registration filing
Hyperfine filed a registration statement on May 12, 2026, providing details about a securities offering with the SEC.
Hyperfine, Inc. to Participate in Upcoming 2026 Jefferies Global Healthcare Conference
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI syste...